Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : ICOS Corporation -- Ignore unavailable to you. Want to Upgrade?

To: Ian@SI who wrote (769)	6/3/2000 12:57:00 PM
From: Cacaito	Read Replies (1) \| Respond to of 1139

Be happy with $500M, cause: ""Cialis is a $500 million drug (in annual sales) without the nitrate benefit, and a $1 billion-$2 billion blockbuster with it."" It is very difficult to take out, or minimize, the nitrate add on effect for lower blood pressure. Viagra and Cialis, and the new one from Bayer in development, works at enhancing the availability of nitric oxide(viagra and the like are savers, avoid degradation of nitric oxide), same as the nitrates (nitric oxide donors drugs) eventually both effects will give vasodilation and low blood pressure. Unless Cialis is more receptor specific (icos/lly say so, I do not believe it until proven in trials and open market), a very difficult task cause to get the expected action it will be difficult to avoid similar receptors affinities, but if it is true that the vision problems are not happening, then the target receptor affinity "seems" to be more specific than Viagra. Cialis is just to build up strength, Pafase will be the huge money maker, it will make Cialis, and maybe even Viagra pale in comparison.